📰 Human Use News
Page 134 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
June 23, 2022
Novartis receives approval from the European Commission for Tabrecta for the treatment of non-small cell lung cancer - News - PharmaTimes
June 23, 2022
Upon authorization, Nuvaxovid would be the first protein-based option for adolescents aged 12 through 17 in Europe Nuvaxovid demonstrated 80% efficacy and was generally well-tolerated in adolescents GAITHERSBURG, Md., June 24, 2022 /PRNewswire/ --Novavax,Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine has been recommended for expande...
June 23, 2022
/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...
June 23, 2022
The EC has authorised a variation of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) to treat patients with mild, moderate or severe renal impairment.
June 23, 2022
STOCKHOLM, June 23, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company...
June 23, 2022
Full text of 14th BRICS Summit Beijing Declaration-
June 23, 2022
The company's COVID-19 vaccine could soon be available to adolescents in the European Union.
June 23, 2022
Upon authorization, Nuvaxovid would be the first protein-based option for adolescents aged 12 through 17 in EuropeNuvaxovid demonstrated 80% efficacy and was generally well-tolerated in adolescentsGAITHERSBURG
June 23, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
June 23, 2022
France-based Valneva SE announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended marketing authorization for Valneva's inactivated whole-virus COVID-19 vaccine, VLA2001, for use as primary vaccination in people from 18 to 50 years of age. The CHMP concluded by consensus after a thorough evaluation that "the data on the vaccine were robust and met the EU criteria for efficacy, safety, and quality."